Stocktoria
Orchestra BioMed Holdings, Inc. OBIO
Orchestra BioMed Holdings, Inc. (OBIO) earns a Piotroski F-score of 5/9 (mixed financial health), with an Altman Z″ in the distress zone. It does not currently pay a dividend. FY2025 revenue was $33.5M at a -157.4% net margin.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 5/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″ components · distress zone
| Component | Value |
|---|---|
| Working capital / assets | 0.794 |
| Retained earnings / assets | -3.157 |
| EBIT / assets | -0.451 |
| Equity / liabilities | 1.041 |
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| OBIO | Orchestra BioMed Holdings, Inc. | 5/9 | -7.02 | — | — |
| SSKN | STRATA Skin Sciences, Inc. | 4/9 | — | — | -8.5% |
| CTSO | Cytosorbents Corp | 3/9 | — | — | +4.1% |
| UTMD | UTAH MEDICAL PRODUCTS INC | 3/9 | — | — | -5.8% |
| IDXG | INTERPACE BIOSCIENCES, INC. | 4/9 | -16.52 | 1.9 | -17.5% |
| SRTS | Sensus Healthcare, Inc. | 4/9 | 14.36 | — | -34.3% |
| KRMD | KORU Medical Systems, Inc. | 4/9 | -0.06 | — | +22.2% |
About Orchestra BioMed Holdings, Inc.
Orchestra BioMed Holdings, Inc. operates as a biomedical company in the United States. The company's flagship product candidates include Atrioventricular Interval Modulation, a bioelectronic therapy candidate designed to immediately, substantially, and persistently lower blood pressure; and Virtue Sirolimus AngioInfusion Balloon for the treatment of atherosclerotic artery disease. It also develops Cardiac Neuromodulation Therapy for heart failure, or potential treatment of clinical indications, such as urology or osteoarthritis; and CNT-HF, a bioelectronic product candidate that aims to reduce chronic sympathetic nervous system activity in heart failure. In addition, the company offers FreeHold devices and additional minimally invasive surgery enabling devices; and Pure-Vu system, a medical device to facilitate the cleansing of a poorly prepared gastrointestinal tract during colonoscopy and upper gastrointestinal endoscopy procedures. It has a collaboration agreement with Medtronic, Inc. for the development of AVIM therapy for the treatment of HTN in pacemaker-indicated patients; and a strategic collaboration with Terumo Corporation and Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral vascular disease. Orchestra BioMed Holdings, Inc. was founded in 2018 and is headquartered in New Hope, Pennsylvania.
FAQ
Is OBIO financially healthy?
Orchestra BioMed Holdings, Inc.'s Piotroski F-score is 5/9 (8–9 is excellent, 0–3 weak), and its Altman Z″ distress score is in the distress zone.
Does OBIO pay a dividend?
No, Orchestra BioMed Holdings, Inc. does not currently pay a dividend.
How profitable is OBIO?
In FY2025, Orchestra BioMed Holdings, Inc. had a net margin of -157.4% and a return on equity of -98.4%.
What is the analyst price target for OBIO?
The average Wall-Street price target for Orchestra BioMed Holdings, Inc. is $12.17, about 175.3% above the recent price, from 6 analysts.
Is OBIO a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Orchestra BioMed Holdings, Inc.: a Piotroski F-score of 5/9, an Altman Z″ in the distress zone. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.